PEDIATRICS Vol. 35 No. 4 April 1965, pp. 720
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KRUGMAN, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by KRUGMAN, S.

Letters to the Editor

SAUL KRUGMAN M.D.1

1 Professor and Chairman, Department of Pediatrics, New York University School of Medicine, 550 First Avenue, New York, New York, 10016

In the introduction to our article (Pediatrics, 34:795, 1964) it is clearly stated that one inoculation of live measles vaccine is the immunization of choice for infants over 9 months of age. This regimen has obvious advantages over the combined inactivated-live measles vaccination procedures which entail multiple inoculations. On the other hand, live vaccine is not consistently immunogenic for younger infants because of the potential suppressive effect of residual passive antibody.

Passively acquired measles antibody may disappear as early as 3 months or as late as 11 months.